

Prostate Cancer Biomarkers and Their Role in the MRI Era

Peter K.F. Chiu, MD

References

- Alberts, A. R., Roobol, M. J., Verbeek, J. F., Schoots, I. G., Chiu, P. K., Osses, D. F., ... & Arsov, C. (2019). Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European randomized study of screening for prostate cancer risk calculators. *European urology*, *75*(2), 310-318.
- Andriole, G. L., Crawford, E. D., Grubb III, R. L., Buys, S. S., Chia, D., Church, T. R., ... & Berg, C. D. (2009). Mortality results from a randomized prostate-cancer screening trial. *New England journal of medicine*, *360*(13), 1310-1319.
- Ankerst, D. P., Straubinger, J., Selig, K., Guerrios, L., De Hoedt, A., Hernandez, J., ... & Vickers, A. J. (2018). A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. *European urology*, *74*(2), 197-203.
- Auvinen, A., Rannikko, A., Taari, K., Kujala, P., Mirtti, T., Kenttämies, A., ... & Tammela, T. L. (2017). A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. *European journal of epidemiology*, *32*, 521-527.
- Baston, C., Preda, A., Iordache, A., Olaru, V., Surcel, C., Sinescu, I., & Gingu, C. (2024). How to Integrate Prostate Cancer Biomarkers in Urology Clinical Practice: An Update. *Cancers*, *16*(2), 316.
- Chiu, P. K. F., Leow, J. J., Chiang, C. H., Mok, A., Zhang, K., Hsieh, P. F., ... & Huang, C. Y. (2023). Prostate Health Index density outperforms prostate-specific antigen density in the diagnosis of clinically significant prostate cancer in equivocal magnetic resonance imaging of the prostate: a multicenter evaluation. *The Journal of Urology*, *210*(1), 88-98.
- Chiu, P. K., Lam, T. Y., Ng, C. F., Teoh, J. Y., Cho, C. C., Hung, H. Y., ... & Sung, J. J. (2023). The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men. *Asian Journal of Andrology*, *25*(6), 674-679.
- Chiu, P. K. F., Fung, Y. H., Teoh, J. Y. C., Chan, C. H., Lo, K. L., Li, K. M., ... & Ng, C. F. (2021). Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer. *Prostate Cancer and Prostatic Diseases*, *24*(2), 542-548.
- Chiu, P. K. F., Lai, F. M. M., Teoh, J. Y. C., Lee, W. M., Yee, C. H., Chan, E. S. Y., ... & Ng, C. F. (2016). Prostate health index and% p2PSA predict aggressive prostate cancer pathology in Chinese patients undergoing radical prostatectomy. *Annals of surgical oncology*, *23*, 2707-2714.
- Chiu, P. K. F., Ng, C. F., Semjonow, A., Zhu, Y., Vincendeau, S., Houlgatte, A., ... & Roobol, M. J. (2019). A multicentre evaluation of the role of the prostate health index (PHI) in regions with

differing prevalence of prostate cancer: adjustment of PHI reference ranges is needed for European and Asian settings. *European urology*, 75(4), 558-561.

- Chiu, P. K. F., Ng, C. F., Semjonow, A., Zhu, Y., Vincendeau, S., Houlgatte, A., ... & Roobol, M. J. (2019). A multicentre evaluation of the role of the prostate health index (PHI) in regions with differing prevalence of prostate cancer: adjustment of PHI reference ranges is needed for European and Asian settings. *European urology*, 75(4), 558-561.
- Chiu, P. K., Roobol, M. J., Nieboer, D., Teoh, J. Y., Yuen, S. K., Hou, S. M., ... & Ng, C. F. (2017). Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population. *Prostate Cancer and Prostatic Diseases*, 20(1), 99-104.
- Chiu, P. K. F., Teoh, J. Y. C., Lee, W. M., Yee, C. H., Chan, E. S. Y., Hou, S. M., & Ng, C. F. (2016). Extended use of Prostate Health Index and percentage of [-2] pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination. *Investigative and Clinical Urology*, 57(5), 336.
- Chiu, P. K., Teoh, J. Y., Lee, W. M., Yee, C. H., Chan, E. S., Hou, S. M., & Ng, C. F. (2016). Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination. *Investigative and clinical urology*, 57(5), 336–342. <https://doi.org/10.4111/icu.2016.57.5.336>
- Desai, M. M., Cacciamani, G. E., Gill, K., Zhang, J., Liu, L., Abreu, A., & Gill, I. S. (2022). Trends in incidence of metastatic prostate cancer in the US. *JAMA Network Open*, 5(3), e222246-e222246.
- Gilgunn, S., Conroy, P. J., Saldova, R., Rudd, P. M., & O'kenney, R. J. (2013). Aberrant PSA glycosylation—a sweet predictor of prostate cancer. *Nature Reviews Urology*, 10(2), 99-107.
- Haese, A., Trooskens, G., Steyaert, S., Hessels, D., Brawer, M., Vlaeminck-Guillem, V., ... & Van Criekinge, W. (2019). Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer before initial prostate biopsy. *The Journal of urology*, 202(2), 256-263.
- Hansen, J., Auprich, M., Ahyai, S. A., De La Taille, A., Van Poppel, H., Marberger, M., ... & Chun, F. K. (2013). Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. *European urology*, 63(2), 201-209.
- Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., ... & Dahm, P. (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. *bmj*, 362.
- Isotani, S., Chiu, P. K. F., Ashizawa, T., Fung, Y. H., Ieda, T., China, T., ... & Horie, S. (2023). Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men. *Prostate International*, 11(3), 180-185.

- Ito, K., & Kimura, T. (2023). Complex epidemiology of prostate cancer in Asian countries. *Journal of Urologic Oncology*, 21(1), 5-13.
- Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., ... & Moore, C. M. (2018). MRI-targeted or standard biopsy for prostate-cancer diagnosis. *New England Journal of Medicine*, 378(19), 1767-1777.
- Kim, J. Y., Jeon, S. S., Chung, J. H., Lee, S. S., & Park, S. W. (2023). How to avoid prostate biopsy in men with Prostate Image-Reporting and Data System 3 lesion? Development and external validation of new biopsy indication using prostate health index density. *Prostate International*, 11(3), 167-172.
- Kim, M. J., Park, J. J., Kang, K. A., Park, S. Y., & Kim, C. K. (2024). Utility of Prostate Health Index Density for Biopsy Strategy in Biopsy-Naïve Patients With PI-RADS v2. 1 Category 3 Lesions. *Journal of Magnetic Resonance Imaging*.
- McKiernan, J., Donovan, M. J., O'Neill, V., Bentink, S., Noerholm, M., Belzer, S., ... & Carroll, P. (2016). A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. *JAMA oncology*, 2(7), 882-889.
- Ng, C. F., Chiu, P. K., Lam, N. Y., Lam, H. C., Lee, K. W., & Hou, S. S. (2014). The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL. *International urology and nephrology*, 46, 711-717.
- Nordström, T., Discacciati, A., Bergman, M., Clements, M., Aly, M., Annerstedt, M., ... & Akrawi, S. (2021). Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. *The Lancet Oncology*, 22(9), 1240-1249.
- Rawla, P. (2019). Epidemiology of prostate cancer. *World journal of oncology*, 10(2), 63.
- Russo, G. I., Regis, F., Castelli, T., Favilla, V., Privitera, S., Giardina, R., ... & Morgia, G. (2017). A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-kallikrein panel score in predicting overall and high-grade prostate cancer. *Clinical genitourinary cancer*, 15(4), 429-439.
- Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Ciatto, S., Nelen, V., ... & Auvinen, A. (2009). Screening and prostate-cancer mortality in a randomized European study. *New England journal of medicine*, 360(13), 1320-1328.
- Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V., ... & Auvinen, A. (2014). Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. *The Lancet*, 384(9959), 2027-2035.

- Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L. J., Recker, F., Páez, A., Määtänen, L., Bangma, C. H., Aus, G., Carlsson, S., Villers, A., Rebillard, X., van der Kwast, T., ... ERSPC Investigators (2012). Prostate-cancer mortality at 11 years of follow-up. *The New England journal of medicine*, 366(11), 981–990. <https://doi.org/10.1056/NEJMoa1113135>
- Song, B., Song, S. H., Hwang, S. I., Lee, H. J., Lee, H., Hong, S. K., ... & Lee, S. (2023). Clinical value of prostate health index as an indicator for recommending magnetic resonance imaging in patients with gray-zone prostate-specific antigen level. *World Journal of Urology*, 41(12), 3519-3526.
- Stovsky, M., Klein, E. A., Chait, A., Manickam, K., Stephenson, A. J., Wagner, M., ... & Zaslavsky, B. (2019). Clinical validation of IsoPSA™, a single parameter, structure based assay for improved detection of high grade prostate cancer. *The Journal of Urology*, 201(6), 1115-1120.
- Thomas, J., Atluri, S., Zucker, I., Reis, I., Kwon, D., Kim, E., ... & Punnen, S. (2023, October). A multi-institutional study of 1,111 men with 4K score, multiparametric magnetic resonance imaging, and prostate biopsy. In *Urologic Oncology: Seminars and Original Investigations* (Vol. 41, No. 10, pp. 430-e9). Elsevier.
- Tomlins, S. A., Day, J. R., Lonigro, R. J., Hovelson, D. H., Siddiqui, J., Kunju, L. P., ... & Chinnaiyan, A. M. (2016). Urine TMPRSS2: ERG plus PCA3 for individualized prostate cancer risk assessment. *European urology*, 70(1), 45-53.
- Tosoian, J. J., Trock, B. J., Morgan, T. M., Salami, S. S., Tomlins, S. A., Spratt, D. E., ... & Chinnaiyan, A. M. (2021). Use of the MyProstateScore test to rule out clinically significant cancer: validation of a straightforward clinical testing approach. *The Journal of urology*, 205(3), 732-739.
- Tosoian, J. J., Singhal, U., Davenport, M. S., Wei, J. T., Montgomery, J. S., George, A. K., ... & Morgan, T. M. (2022). Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need. *Urology*, 164, 184-190.
- Tsoi, T. H., Chan, C. F., Chan, W. L., Chiu, K. F., Wong, W. T., Ng, C. F., & Wong, K. L. (2016). Urinary polyamines: a pilot study on their roles as prostate cancer detection biomarkers. *PLoS One*, 11(9), e0162217.
- Wagaskar, V. G., Levy, M., Ratnani, P., Sullimada, S., Gerenia, M., Schlüssel, K., ... & Tewari, A. (2023). A SelectMDx/magnetic resonance imaging-based nomogram to diagnose prostate cancer. *Cancer Reports*, 6(1), e1668.
- Wang, W. L. W., Sorokin, I., Aleksic, I., Fisher, H., Kaufman Jr, R. P., Winer, A., ... & Tenniswood, M. (2020). Expression of small noncoding RNAs in urinary exosomes classifies prostate cancer into indolent and aggressive disease. *The Journal of urology*, 204(3), 466-475.